Coccidioidomycosis manifests as a variety of clinical manifestations and ranges in severity from asymptomatic exposure with resultant immunity to reinfection, to fulminant, and life-threatening disseminated disease. Primary coccidioidal pneumonia represents the most common clinical form of infection, and the incidence continues to increase. Within the endemic region, primary pulmonary coccidioidomycosis represents up to 29% of all community-acquired pneumonia emphasizing the frequency with which clinicians encounter this endemic mycosis. Chronic infection develops in 3 to 5% of patients, and almost all morbidity and mortality observed in coccidioidomycosis occur in these forms (e.g., chronic pulmonary disease, extrapulmonary manifestations). This review summarizes the ecology, epidemiology, manifestations of disease, and treatment options currently available for coccidioidomycosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0035-1562900 | DOI Listing |
J Vis Exp
December 2024
Department of Medicine, New Jersey Medical School, Rutgers - The State University of New Jersey;
Fungi infect humans when environmental spores are inhaled into the lungs. The lung is a heterogeneous organ. Conducting airways, including bronchi and bronchioles, branch until terminating in the alveolar airspace where gas exchange occurs.
View Article and Find Full Text PDFJ Neurosurg Case Lessons
December 2024
Department of Neurosurgery, University of Mississippi Medical Center, Jackson, Mississippi.
Background: The authors describe the case of a 35-year-old male who presented with back pain and painful masses on his upper extremities. He had a known sacral lesion identified 1 year prior at an outside facility, suspected to be coccidioidomycosis on biopsy, but the workup was not completed because the patient left against medical advice and was lost to follow-up. Computed tomography (CT) and magnetic resonance imaging revealed lytic destructive lesions involving the calvaria, thoracolumbar spine, and sacrum, concerning for an active and disseminated infection.
View Article and Find Full Text PDFInfect Dis Clin North Am
December 2024
Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA, USA; Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA; UC-Davis Center for Valley Fever. Electronic address:
Coccidioidomycosis is the clinical disease caused by the dimorphic pathogenic fungi Coccidioides immitis and C posadasii. The number of clinically recognized coccidioidomycosis cases continues to increase yearly including in regions outside the traditional regions of endemicity. Following inhalation of Coccidioides spores, the course may range from asymptomatic exposure with resultant immunity, to a subacute pulmonary illness, to life-threatening disseminated infection.
View Article and Find Full Text PDFTranspl Infect Dis
December 2024
Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA.
J Antimicrob Chemother
December 2024
Clinical Outcomes Assesments, Clinical Outcomes Solutions, Folkestone, Kent, UK.
Background: Coccidioidomycosis (Valley Fever) is a dimorphic fungal infection endemic to the southwest United States, Mexico, Central and South America, which can lead to chronic debilitating illness and death.
Objectives: This qualitative study was conducted to develop a bespoke patient-reported outcome measure for patients with chronic disseminated coccidioidomycosis to assess health-related quality of life (HRQoL) impacts.
Patients And Methods: Online, first-person narratives of patient experiences of disseminated coccidioidomycosis were used to create a patient-centred conceptual model of symptoms and impacts of the condition.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!